A major study of 14,671 patients from 38 countries with type 2 diabetes and established cardiovascular disease has found that a DPP-4 inhibitor does not increase the risk for major adverse CV events, hospitalisation for heart failure or adverse events.
This content is restricted. If you have already registered on the AJP website please login below, Or you can Register for free.
Register here
